The history of ergot of rye (Claviceps purpurea) III: 1940-80

Journal of the Royal College of Physicians of Edinburgh

Volumn 40, Issue 1, 2010, Pages 77-80

  Lee, M R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Albert Hofmann; Bromocriptine; Dopamine receptors; Ergot; Lysergic acid diethylamide; Psychosis

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR; ERGOCORNINE; ERGOCRYPTINE; ERGOLINE DERIVATIVE; ERGOMETRINE; ERGOTAMINE; ERGOTOXINE; LISURIDE; LYSERGIDE; NIKETHAMIDE; PERGOLIDE; SELEGILINE;

ARTICLE; CENTRAL NERVOUS SYSTEM; CLAVICEPS PURPUREA; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; FIBROSIS; HALLUCINATION; HISTORY; HUMAN; HYPERTENSION; HYPOTENSION; ISOLATION PROCEDURE; LACTATION; NONHUMAN; PARALYSIS; PARKINSON DISEASE; PROLACTINOMA; PSYCHOSIS; RAYNAUD PHENOMENON; SCHIZOPHRENIA; VASOSPASM; VERTIGO; VISUAL HALLUCINATION;

BROMOCRIPTINE; CLAVICEPS; DIHYDROERGOCRYPTINE; ERGOT ALKALOIDS; HISTORY, 20TH CENTURY; HUMANS; LYSERGIC ACID DIETHYLAMIDE; PARKINSON DISEASE; PROLACTINOMA; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; SCOTLAND; SECALE CEREALE;

EID: 77949537824     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2010.115     Document Type: Article

References (16)

1. Holmstedt B, Liljestrand G, editors. Readings in pharmacology. New York: Raven Press; 1981. p. 209-13.
2. Hofmann A. Ergot - a rich source of pharmacologically active substances. In: Swain T, editor. Plants in the development of modern medicine. Cambridge, MA: Harvard University Press; 1972. p. 236-60.
3. Lee MR. The history of ergot II: 1900-40. J R Coll Physicians Edinb 2009; 39:365-9.
4. Stoll A, Hofmann A. [Partial synthesis of alkaloids of the ergonovine type.] Helv Chim Acta 1943; 26:944-65. In German. doi:10.1002/hlca. 19430260326
5. Hofmann A. LSD: my problem child. New York: McGraw Hill; 1980.
6. Stoll WA. [Lysergic acid diethylamide, a hallucinogen from the ergot group.] Schweiz Arch Neut 1947; 60:279. In German.
7. See http://www.erowid.org/references/refs.php for a complete list of LSD research papers.
8. Smart RG, Bateman K. Unfavourable reactions to LSD: a review and analysis of the available case reports. Can Med Assoc J 1967; 97:1214-21.
9. Cohen S. A classification of LSD complications. Psychosomatics 1966; 7:182-6.
10. Obituary: Albert Hofmann. Daily Telegraph; 20 May 2008. Available from: http://www.telegraph.co.uk/news/obituaries/1912485/ Obituary-Albert- Hofmann-LSD-inventor.html
11. Hofmann A, Tscherter H. [Isolation of lysergic acid alkaloids from the Mexican drug ololiuqui (Rivea corymbosa (L.) Hall.f.).] Experientia 1960;16:414. In German. doi:10.1007/BF02178840
12. Stauffacher D, Tscherter H, Hofmann A. [Isolation of ergosine and ergosinine as well as agroclavine from seeds of Ipomoea argyrophylla Vatke (Convolvulaceae). 64. On ergot alkaloids (1)] Helv Chim Acta 1965; 48:1379-80. In German. doi:10.1002/hlca.19650480618
13. Shelesnyak MC. Ergotoxine inhibition of deciduoma formation and its reversal by progesterone. Am J Physiol 1954; 179:301-4.
14. Flückiger E. The pharmacology of bromocriptine. In: Bayliss RIS, Turner P, Maclay WP, editors. Pharmacological and clinical aspects of bromocriptine (Parlodel). Tunbridge Wells: MCS Consultants; 1976. p. 12-26.
15. Giacomini GA. Traité philosophique et expérimental de matière médicale et de thérapeutique. Paris: Bureau de l'encyclopédie; 1839.
16. Joint Formulary Committee. British National Formulary. 57 ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2008. p. 410-2.